O15-Water

DRUG2 trials

Sponsors

MedTrace Pharma A/S, Vaestra Goetalandsregionen

Conditions

Cardiovascular diseaseCoronary Artery Disease

Phase 3

A Phase 3, Multicenter, Open Label Study to Confirm the Diagnostic Potential of Intravenously Administered 15O- H2O to Identify Coronary Artery Disease During Pharmacological Stress and Resting Conditions Using PET Imaging

RecruitingCTIS2023-503843-33-00

MedTrace Pharma A/SCoronary Artery Disease

Start: 2022-05-04Target: 182Updated: 2025-11-17

Prognostic Performance of Quantitative Myocardial Perfusion Imaging Using H2[15O] Positron Emission Tomography in Coronary Artery Disease - The AQUA COR trial

Not yet recruitingCTIS2024-518706-41-01

Vaestra GoetalandsregionenCardiovascular disease

Target: 40000Updated: 2026-06-03